In 1958, Rasmussen and co-workers reported three patients suffering from focal seizures secondary to chronic localized encephalitis. 1 Today, most researchers and epileptologists still use the term Rasmussen encephalitis or Rasmussen syndrome for this particular condition. [2] [3] [4] Here, we prefer to name the entity Rasmussen syndrome (RS) in recognition of Rasmussen's contribution and because of the broader inclusiveness of the term ''syndrome''. RS is a rare and severe immune-mediated brain disease which results in unilateral brain atrophy leading to progressive neurological dysfunction and refractory seizures. 1, 4, 5 Different mechanisms have been suggested, but up to today the etiopathogenesis has not been fully understood. [6] [7] [8] [9] [10] The syndrome should be considered sporadic, since there is no evidence supporting a specific genetic marker. 2, 4 Recently the entity has been described as a distinctive constellation based on specific lesions that are not exactly electroclinical syndromes. 11 This is a diagnostically meaningful category of epilepsy which may have therapeutic implications, particularly for surgery. Most patients with RS are refractory to conventional antiepileptic drugs (AEDs) and the only recommended therapeutic approach is surgical hemispherectomy, which either removes substantial parts of the affected hemisphere or disconnects the hemispheres while removing a minimal amount of cortical structures.
including the patients who were not operated. Inclusion criteria as defined by Bien et al. from the consensus group were considered. 4 In our first 13 patients, who were previously published, 18 we used the inclusion criteria according to Hart and coworkers. 5 
Inclusion criteria
A. Children who develop epilepsia partialis continua and meet at least one of the following criteria to suggest the diagnosis of chronic encephalitis: (1) progressive neurologic deficit at the beginning or after the onset of epilepsia partialis continua, but before the start of treatment; (2) * Progressive means that at least two sequential clinical examinations or MRI studies are required to meet the respective criteria. To indicate clinical progression, each of these examinations must document a neurological deficit, and this must increase over time. To indicate progressive hemiatrophy, each of these MRIs must show hemiatrophy, and this must increase over time.
In addition, if no biopsy is performed, MRI with administration of gadolinium and brain CT scan should be performed to document the absence of gadolinium enhancement and calcifications to rule out the differential diagnosis of a unihemispheric vasculitis. 19 Other immune-mediated epileptic encephalopathies, cerebral vasculitis including lupus erythematosus, subacute measles encephalitis with or without immunodeficiency, hemiconvulsion-hemiplegia-epilepsy syndrome, focal cortical dysplasia including hemimegalencephaly, tumor, stroke, Sturge-Weber syndrome, and neurometabolic diseases particularly mitochondriopathies, were excluded. Most of these entities may be associated with epilepsia partialis continua (EPC).
In this study all patients underwent video-EEG in addition to the routine EEG recordings. Evoked potentials, repeated brain CT scans, and MRIs with or without gadolinium were obtained in all patients. Magnetic resonance spectroscopy was performed in two patients. Neurometabolic studies, especially to rule out mitochondrial disease, were also performed in all cases. CSF studies including oligoclonal bands were performed in 17 patients, and a measles antibody test was done in five. Other studies, such as liver function, and blood and autoantibody tests, were done. Antibodies against the N-methyl-D-aspartate receptor (NMDAR) and mitochondrial DNA genetic testing for mutations were done in four and two patients, respectively. Brain biopsy was performed in four patients. Data on school achievements and neuropsychological evaluations (Terman-Merrill or WISC III or IV) were repeatedly obtained during the follow-up of 2-20 years. In the cases in which formal neuropsychological tests could not be performed, cognitive changes were evaluated based on clinical judgment.
Biochemical tests and urine analysis were performed, and plasma levels of classic AEDs were monitored. The AEDs as well as other treatment options, such as steroids, immunoglobulins, the ketogenic diet, plasmapheresis, and surgical interventions, were analyzed.
Determination of efficacy of AED, corticosteroid, or immunoglobulin treatment, as well as non-pharmacological therapy was based on electroclinical criteria. Response to medical treatment was evaluated according to the percentage of the seizure control (seizure-free, 75-99% of seizure control, 50-74% seizure control, and less than 50% seizure control). Surgical treatment was evaluated according to the Engel classification. 20 
Results

General characteristics
A total of 32 children (20 boys and 12 girls) with RS were identified between March 1990 and June 2012 at the Garrahan Hospital of Buenos Aires, Argentina. We did not find any significant family history of febrile seizures and/or epilepsy. One patient had a personal history of febrile seizures.
Sixteen patients (50%) had a history of infectious disease previous to epilepsy onset. In 12 patients the infectious episode had occurred two months before, and in four others three months before the onset of the seizures.
Brain biopsy was compatible with RS in four patients, and bilateral involvement was found in two of them. The surgical specimens showed abnormalities compatible with RS in 25 patients who underwent surgery. No patients with non-inflammatory pathology or dual pathology were found.
Clinical features
The mean and median ages at onset of the seizures were 6.5 and 7 years, respectively (range, 4-14 years). All of the patients had focal motor seizures, with secondary generalization in 18 (56%); six patients (18%) had somatosensory focal seizures, 10 patients (31%) had generalized tonic seizures, and eight (12.5%) had complex focal seizures. Simple focal seizures were always contralateral to the affected hemisphere. Sixteen patients (50%) had focal motor status epilepticus, and five patients (15.5%) had generalized status epilepticus. Two patients (6%) had drop attacks. Twenty-eight cases (87.5%) had EPC that had started at a mean age of 9.5 years (range, 6-16 years). In three patients (9.5%) EPC was the first manifestation, associated with hemidystonic and hemidyskinetic movements in one. EPC lasted between sixteen hours and three weeks.
Neurologic symptoms other than epilepsy
In the first stages of the disease, hemiparesis was sometimes secondary to Todd's paresis, but became persistent, fluctuating in severity according to the increase of the seizures in all cases. The definitive neurological deficit (hemiparesis) occurred within the first year after onset of the seizures in 10 patients (31%), in the second or third year after seizure onset in 16 patients (50%), and more than three years after seizure onset in six patients (19%). Severe hemiparesis lead four patients to become wheelchair bound. Dysphasia and dysarthria were found in 12 patients (38%), and cortical sensory loss and visual deficits were observed in six (18%) and seven (22%) patients, respectively.
Cognitive impairment and behavioral disturbances were other neurological manifestations that were observed in all patients. Irritability, hyperactivity, and emotional labiality were the most frequent behavioral changes. In the first three years after seizure onset, the patients were found to have learning difficulties, memory loss, and attention deficits.
At the time of surgery, between 2 and 10 years after disease onset, the mean IQ was 56 AE 10 (range, 40-80).
EEG findings
The background activity in the affected hemisphere showed delta and theta slow waves and sleep disorganization at onset in all patients (Fig. 1) . Over time, the slow activities became bilateral, but predominantly in the affected hemisphere in most patients. In the early period, the interictal EEG showed focal epileptiform abnormalities in one hemisphere in 18 patients (56%) (Fig. 2 ) and multifocal abnormalities in 14 patients (44%). The multifocal abnormalities were seen in one hemisphere in 12 patients. Over time, the interictal EEG recordings showed further deterioration; the epileptiform activity increased and started to involve the contralateral hemisphere as well (Fig. 3 ). There was a welllocalized focus in two patients (6%) and there were multifocal epileptiform discharges in one hemisphere in 18 patients (56.5%), multifocal spikes in one hemisphere associated with synchronic bilateral spikes in three patients (9.5%), bilateral multifocal spikes in five patients (15.5%), and multifocal epileptiform activity associated with synchronic bilateral (Fig. 4 ) discharges in four patients (12.5%). Some abnormal epileptiform activity had the appearance of ictal-like or subclinical discharges.
The ictal EEG showed a multifocal origin, but confined to the affected hemisphere in all patients, except in two patients with bilateral hemisphere involvement. The seizures were secondarily generalized in 10 patients (31%). Isolated seizure onset in the unaffected hemisphere additionally to the seizure onset in the affected hemisphere was registered in only one of the 32 patients.
Neuroradiological findings
CT scan and MRI demonstrated progressive unilateral cerebral atrophy in all patients. In the early stages of the disease, mild focal atrophy involved the temporo-insular region associated with enlargement of the ipsilateral horn and Sylvian fissure in 25 patients (81%) (Fig. 5A and B ). An abnormal cortical and/or subcortical hyperintense signal in T2 and Flair images was observed in 17 patients (53%). T2 hyperintensity and atrophy in the basal ganglia, particularly in the caudate nucleus, were documented in five patients (15.5%) (Fig. 6A and B) . Atrophy of the contralateral cerebellar hemisphere was observed in one patient and of the entire cerebellum in another. Magnetic resonance spectroscopy showed decreased N-acetyl-D-aspartate signal intensity over the entire affected hemisphere in two patients. Functional imaging was not done in any of the patients in this series.
Laboratory tests
Neurometabolic studies in blood and urine were normal in all cases. Cerebrospinal fluid was normal in 18 patients (56%), a mild increase in lymphocytes was found in 10 patients (31%), and protein was increased in nine patients (28%). Oligoclonal bands were positive in 13 patients (40.5%). Anti-glutamate receptor 3 and other antibodies were not performed in our series of patients. Antibodies against the N-methyl-D-aspartate receptor (NMDAR) were not found in four and mitochondrial DNA genetic testing for mutations did not show abnormalities in two patients.
Treatment
The seizures were refractory to all different schemes of classic and new AEDs used. None of the AEDs avoided progression of the disease. High-dose prednisone (2-3 mg/kg/day) was indicated for a period between 6 and 36 months in 30 patients, and intravenous immunoglobulin, three days at 400 mg/kg/day administered monthly, was used in 29 patients for 6-24 months. Corticosteroids associated with immunoglobulins were used in 25 patients for a period of 6-24 months. A transient cessation of progression of the neurological deterioration and a 25-75% seizure reduction was observed in 14 of 25 patients receiving this combination; EPC disappeared in 12 of 30 patients who received corticosteroids and immunoglobulins alone or in combination.
Two patients received the ketogenic diet for 6 and 12 months, respectively. In both patients a 50% seizure reduction was achieved. The patient with bilateral cerebral involvement underwent vagus nerve stimulation and a 30% seizure reduction was achieved after six months of follow-up. Other immunomodulatory treatments, such as monoclonal antibodies, plasmapheresis, and immunosuppressive drugs as well as antiviral treatments, were not indicated in our series of patients. Five patients did not meet the criteria for surgery, and two others refused surgical treatment. Surgical treatment was performed after hemiparesis had become fixed in 25 patients: In 10 patients the modified Villemure technique 12 was performed, consisting of a peri-insular linear corticectomy -preserving the operculum -until the lateral ventricule is opened from the frontal to the temporal horn, followed by section of the frontal horizontal fibers, complete callosotomy, section of the fornix, disconnection of the posterior temporal lobe and amygdalectomy. In 10 patients the classic Rasmussen technique 13,15 modified with temporal lobe disconnection was performed, and hemispherotomy was performed in the remaining five patients. 13 In this series of patients, extradural hematomata were observed in two patients, an aseptic meningeal reaction occurred in two other patients, and placement of a shunt was necessary in one patient due to hydrocephalus.
Outcome
At the last control after a mean age of 13 years of follow-up (range, 2-20 years), good surgical outcome -Engel class I -was observed in 23 (92%) of 25 patients operated. Twenty of them were in Engel class Ia, and the other three in Engel class Ib. In two of 25 patients who underwent surgery seizures continued; both had bilateral electroclinical features and neuroradiological imaging of brain involvement, and pathological findings compatible with RS. Hemiparesis remained unchanged in all patients operated, except the fine finger movements, which deteriorated in fifteen and improved in two of 25 patients operated. All patients developed independent gait after surgery. The outcome for visual fields remained unchanged if already impaired or worsened following surgery. After surgery, neuropsychological performance improved in 10 children only. Seven patients showed dysphasia in the immediate postsurgical period, which improved during follow-up. Of the nine patients who had had preoperative behavioral problems, seven improved significantly after surgery and behavior remained unchanged in two. All children who improved motor, neuropsychological, and behavioral performance had become seizure free. Quality of life improved in all patients who became seizure free and antiepileptic drugs could be reduced in all 25 patients after surgery.
The seven patients who did not undergo surgery continue having refractory seizures. Four of them have not developed fixed hemiparesis yet and were not offered surgical treatment, and one had bilateral brain involvement. The parents of two other patients refused surgical treatment. Both patients who have shown to be refractory to surgery also continue having seizures at 18 and 12 years of age after six and four years of follow-up, respectively.
Discussion
Here we present a series of 32 patients who fulfilled the diagnostic criteria of RS with a long-term follow-up and who had a good response to surgical treatment. Corticosteroid and intravenous immunoglobulin treatments allowed for a transient cessation of progression of the neurological deterioration and control of the seizures including EPC. The presence of refractory unilateral focal and multifocal seizures, EPC, and progressive neurological and neuroradiological involvement of one hemisphere is suggestive of RS. Early recognition is crucial to initiate adequate therapeutic management of this severe epileptic syndrome. RS is the most frequent progressive syndrome associated with EPC.
Formal diagnostic criteria for RS were first proposed in 1994 by Hart et al. 5 Our group had the possibility to participate in this interesting collaborative study. Subsequently, the European consortium compounded these criteria with new data from advanced neuroimaging techniques that better characterized the morphological aspects of the disease. 4 The clinical criteria proposed include a two-step diagnostic approach: If the hallmark clinical, EEG, and imaging criteria are fully met, the diagnosis may be established without the need for a brain biopsy, however, if the criteria are not fulfilled, the progression of clinical deficits must be associated with progressive hemispheric atrophy, as documented by sequential MRIs or alternatively, by characteristic histopathological findings. 4, 21, 22 It should be stressed that the progression of the neurological deficit and the worsening of unilateral brain damage must be confirmed in at least two sequential examinations, and when the brain biopsy is not performed, MRI with gadolinium and CT scan are required to rule out unihemispheric vasculitis. The last inclusion criteria for the diagnosis of RS proposed 4 are more inclusive compared with the previous ones. 5 Future discussion on the inclusion criteria may be necessary in order to make them as effective as possible for early diagnosis of the syndrome and facilitate the planning of adequate medical and surgical treatment. Finally, an accurate diagnostic work up should rule out all the conditions characterized by unilateral neurological syndromes or EPC, as well as inflammatory diseases mimicking RS. 23 We found 32 consecutive patients with RS over 22 years (1.5 new patients per year) at our department. Although our center is the only public hospital where these patients may be operated, some patients are treated in a private setting and diagnosis of other patients with RS may be missed. Thus, the incidence of RS found in this study probably does not reflect the incidence of this particular syndrome in Argentina, and a comparison with the incidence found in Germany by Bien et al. may not be accurate. 17 The management of this severe syndrome should include the treatment of clinical manifestations and of the underlying inflammation. 4, 5, [24] [25] [26] According to the different clinical manifestations and phases of the disease, the therapeutic strategy includes both medical and surgical options. Additionally, treatment alternatives must be taken into account according to the needs of individual patients. [27] [28] [29] [30] [31] Oral and intravenous corticosteroids are the most effective medical treatment in terms of seizure control and neurological deterioration, but long-term efficacy has not been confirmed. 5, 17, 21, 25, 26 Intravenous immunoglobulins have also been reported to be effective in an important proportion of patients with RS, improving seizure control and motor and cognitive alterations. 5, 18, 31 The use of a combination of corticosteroids and immunoglobulins was also effective in the control of seizures and with prominent basal ganglia involvement and predominant movement disorders associated with hemiparesis and contralateral brain MRI abnormalities has been described, and may lead to misdiagnosis. 4, 22, 23, 38 We observed basal ganglia involvement in only five patients. This may be due to the fact that when the first patients with RS were recognized, neuroradiological images were of too low a resolution to detect this type of finding, and hence they were not identified in this retrospective study. Bilateral involvement of the brain in patients within the first months of the disease and in those with long-standing disease probably due to a secondary epileptogenesis has been reported. 39 We found bilateral involvement in two patients of our series. Patients with RS associated with other pathologies, such as lowgrade tumors, cortical dysplasia, tuberous sclerosis, vascular malformations and old ischemic lesions -a so-called double pathology -have also been described. [40] [41] [42] [43] Clinical and imaging findings resembling RS have recently been reported in patients with gliomatosis, granulomatosis, and porphyria, [44] [45] [46] [47] [48] [49] however, pathological evidence of their association is lacking. At onset RS may be confused with a number of non-progressive and progressive diseases with EPC and/or focal or unilateral brain damage. 18, 23, 50, 51 The differential diagnoses of RS are listed in Table 1 .
Conclusion
We present a series of 32 patients who fulfilled the diagnostic criteria of RS with a long-term follow-up.
Corticosteroid and intravenous immunoglobulin treatment, alone or in combination, should be considered in the early stages of the disease. These therapeutic alternatives allow for a transient cessation of progression of the neurological deterioration and control of the seizures including EPC, but almost all patients finally undergo surgery.
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